Published in final edited form as:

Medchemcomm. 2015 ; 6: 1278–1284. doi:10.1039/C5MD00198F.

Discovery, synthesis and structure-activity analysis of symmetrical 2,7-disubstituted fluorenones as urea transporter inhibitors

Sujin Lee^a, Cristina Esteva-Font^a, Puay-Wah Phuan^a, Marc O. Anderson^b, and A.S Verkman^a

^aDepartments of Medicine and Physiology, University of California, San Francisco CA, 94143-0521 USA

^bDepartment of Chemistry and Biochemistry, San Francisco State University, San Francisco CA, 94132-4136 USA

Abstract

Kidney urea transporters are targets for development of small-molecule inhibitors with action as salt-sparing diuretics. A cell-based, functional high-throughput screen identified 2,7-bisacetamido fluorenone **3** as a novel inhibitor of urea transporters UT-A1 and UT-B. Here, we synthesized twenty-two 2,7-disubstituted fluorenone analogs by acylation. Structure-activity relationship analysis revealed: (a) the carbonyl moiety at C9 is required for UT inhibition; (b) steric limitation on C2, 7-substituents; and (c) the importance of a crescent-shape structure. The most potent fluorenones inhibited UT-A1 and UT-B urea transport with IC₅₀ ~ 1 μM. Analysis of in vitro metabolic stability in hepatic microsomes indicated metabolism of 2,7-disubstituted fluorenones by reductase and subsequent elimination. Computational docking to a homology model of UT-A1 suggested UT inhibitor binding to the UT cytoplasmic domain at a site that does not overlap with the putative urea binding site.

The kidney expresses urea transporter (UT) proteins, which facilitate the passive transport of urea across cell plasma membranes in a subset of kidney tubules and microvessels.¹ SLC14A1 and SLC14A2 genes encode UT-A and UT-B urea transporters, respectively.² Studies in mice lacking UTs^{3–7} and in rodents treated with UT inhibitors^{8–10} indicate that UT-A1, the UT-A isoform expressed at the apical membrane of epithelial cells in inner medullary collecting duct, is the principal target for diuretic development. Absence or inhibition of UTs impairs urinary concentrating function, producing a diuretic response. UT inhibitors are thus development candidates as first-in-class salt-sparing diuretics for therapy of various edema states and hyponatremias, such as those associated with congestive heart failure and cirrhosis.^{11–13}

Our lab previously developed high-throughput functional assays of UT-A¹⁴ and UT-B¹⁵ urea transporters. Several classes of small-molecule inhibitors of the target UT-A1 were

[†]Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

identified.^{10, 14} In proof-of-concept studies, two classes of inhibitors with low micromolar IC₅₀ produced a diuretic response in rats;¹⁰ however, their inhibition potency and metabolic stability were not optimal for further development. Additional screening reported here identified symmetrical, disubstituted fluorenones as novel UT inhibitors. Because of the drug-like properties of tricyclic fluorenones and the absence of a commercial source to obtain analogs for structure-activity relationship analysis, here we synthesized 22 symmetrical, disubstituted fluorenones, measured their UT inhibition activity and selectivity, analyzed their inhibition and metabolism mechanisms, and used homology modeling and computational docking to propose binding sites on UT-A and UT-B.

A UT-A1 inhibition screen of 50,000 compounds identified 2,7-bisacetamidofluorenone **3** as a UT-A1 inhibitor with IC₅₀ ~1 μ M that produced complete inhibition at higher concentrations (Fig. 1A). Fluorenone **3** also inhibited UT-B with similar potency. The fluorenone scaffold has not been previously reported for the inhibition of urea transporters, though there are prior reports of biological activities of this compound class. Tiloron is an orally bioavailable antiviral agent^{16, 17} and an immunomodulator.¹⁸ The antitumor activity of fluorenone derivatives has been shown to be result from inhibition of telomerase and DNA topoisomerase I.^{19–21} Most reported fluorenone analogs focused on 2,7-bis-ester or ether moieties, unlike the bis-acetamidofluorenone **3** identified from the UT-A1 screen. The 2,7-bis-acetamido fluorenone structure has drug-like properties, including favorable molecular weight (294 Da), topological surface area (75.2 Å²) and cLogP (2.12), which fall within the Lipinski²² and Veber²³ criteria for orally bioavailable drugs.

Based on the potency and physicochemical properties of **3**, a series of 2,7-disubstituted fluorenone analogs were rationally designed to identify more potent urea transport inhibitors and to establish structure-activity relationships. Structurally, fluorenone **3** is a symmetrical, rigid crescent-shaped molecule with a carbonyl group at the 9-position and bisacetamido groups at the 2 and 7 positions.

As diagrammed in Fig. 1B, analogs were designed to include: i) different functional groups on the 2,7-diamino position; ii) different non-carbonyl functional groups at the 9-position; and iii) flexible and ring strain-released scaffolds. In a preliminary study, testing of ~70 commercially available fluorenone analogs did not identify active analogs.

Scheme 1 shows the synthetic approaches for the preparation of 2,7-bis(alkylamido)fluorenones **3–10**. Reduction of commercially available 2,7-dinitrofluoren-9-one **1** using sodium sulfide nonahydrate and sodium hydroxide afforded the key intermediate 2,7-diamino-fluoren-9-one **2**.¹⁹ The re-synthesis of **3** was accomplished by acetylation of **2** using acetic anhydride. Additional acyl analogs of **3** were similarly prepared by reaction of **2** with the respective acyl reagents under basic condition to yield propionyl, isobutyryl and butyryl analogs **4**, **5** and **6** respectively. We next prepared the bio-isostere analogs of **3**, trifluoroacetamide **7**, carbamate **8** and methanesulfonamide **9**. Treatment of **2** with trifluoroacetic acid and heating to reflux in a sealed tube afforded trifluoroacetamide **7**.²⁴ The carbamate analog **8** was synthesized by reaction of **2** with potassium isocyanate.²⁵ Sulfonamide analog **9** was prepared by mesylation in pyridine. The γ -sultam **10** was synthesized using chloropropansulfonyl chloride and subsequent cyclization with potassium

carbonate. As shown in Scheme 2, analogs with extended chains on the amide bond were synthesized. Bromoacetamido **11** and benzyloxyacetamido **15** were synthesized from **2** using corresponding acyl halides in refluxing xylene. Using maleic anhydride in refluxing chloroform gave the maleamic acid analog **16**. Further substitution reaction of **11** using methoxyethanol with sodium hydride afforded **13**, and with sodium hydroxide and sodium azide gave the corresponding amide analogs **12** and **14**, respectively.

To investigate the importance of the carbonyl at the 9-position for urea transport inhibition, we synthesized oxime **17**, hydroxyl **18** and sulfone **20** (Scheme 3). Condensation of 2,7-bisacetamido fluoren-9-one **3** with hydroxylamine hydrochloride in pyridine afforded oxime analog **17**. Ketone reduction of **3** with sodium borohydride in methanol gave hydroxyl analog **18**. Acylation of commercially available 2,7-diaminodiphenylenesulfone **19** afforded the bisacetamidodiphenylsulfone **20**. To prepare flexible ring acyclic analogs, commercially available 3,3'-diaminobenzophenone **21** was acylated and sulfonated to give bisacetamide **22**, benzyloxyacetamide **23** and bismethanesulfonamidobenzophenone **24**.

Table 1 summarizes IC₅₀ values for inhibition of UT-A1 and UT-B urea transport by the 2,7-disubstituted fluorenones **1–24**. Most analogs showed similar IC₅₀ for inhibition of UT-A1 and UT-B urea transport. Non-substituted fluorenones (**1**, **2** and **21**) were inactive. Elongation of the carbon chain on the amide reduced inhibition, comparing acetamide **3** to propionyl **4**, isobutyryl **5**, maleamic acid **16** and butyryl **6**. Linear ether linkage analogs with elongated side chain also reduced inhibition. Hydroxyacetamide **12** had low activity, and benzyloxyacetamides **15** and **13** were inactive. Replacing acetamide with methanesulfonylamide **9** and carbamate **8** slightly reduced activity. Addition to the acetamide of one more atom - hydroxyl **12**, methyl **4** or bromide **11** - reduced activity. These findings implicate a narrow size limitation for substituents. Interestingly, trifluoroacetamide **7**, which has the same carbon length as **3**, was much less active, indicating that steric and electronic effects also influence inhibition.

The influence of the carbonyl moiety was determined by comparing UT-A1 inhibition by **3**, **17**, **18** and **20**. These analogs contain acetamide on the C2 and C7 positions, but activity was reduced greatly by replacing the carbonyl with oxime **17**, sulfone **20** or hydroxyl **18** moieties (IC₅₀ 12 to >50 μM), suggesting that a hydrogen bond acceptor is necessary on the carbonyl. Interestingly, sulfone **20** showed UT-B selectivity with IC₅₀ of 2 μM for UT-B compared to 15 μM for UT-A1.

Fig. 2A shows concentration-inhibition data for UT-A1 and UT-B inhibition by **3** and analogs **7**, **9** and **22**. Fig. 2B shows original concentration-inhibition curves for **3** (left panel). The *in vitro* characterization of **3** revealed complete reversibility for inhibition of UT-A1 (second panel), rapid inhibition kinetics with complete inhibition by 40 seconds (third panel), and a non-competitive inhibition mechanism in which apparent IC₅₀ was independent of urea concentration (right panel).

To investigate the potential utility of disubstituted fluorenones for UT inhibition in animal studies, *in vitro* microsomal stability measurements were made using an established assay in which compounds were incubated with rat liver microsomes in the presence of NADPH.²⁶

For **3**, 60% remained after 15 min (Fig. 3A). Oxidation catalyzed by the cytochrome P450 monooxygenase, a well-known metabolic reaction on aromatic compounds, was not detected from LC/MS analysis. Instead, a peak at [M+H-16] was detected that increased over time (Fig. 3B). Generation of a [M+H-16] metabolite suggests loss of oxygen, suggesting that bisacetamidofluorenone metabolism involves the mechanism proposed in Fig. 4. Carbonyl reduction of 2,7-dinitrofluorenone by rat liver enzymes utilizing NADH/NADPH has been reported, although the specific carbonyl reduction enzyme was not established.²⁷ Following reduction of carbonyl on fluorenone, the amide proton is readily removed by base-catalyzed elimination to give 2-iminofluorene **25**. To support this proposed mechanism, fluorenone **18** was subjected to basic condition (1M NaOH). The eliminated product **25** could be isolated after 1 hour in ~60% yield, and matched [M+H-16].²⁸ Also, to confirm this proposed mechanism, metabolic stability was studied for oxime **17**, bisacetaminobiphenylacetone **22** and bisacetaminosulfone **20**, which do not contain a carbonyl moiety and thus cannot undergo carbonyl reduction/base-catalyzed elimination sequence. We found that **17**, **20** and **22** were relatively stable compared to fluorenone **3** (>80% remaining at 15 min), and [M+H-16] was not detected by LC/MS (data not shown).

Interestingly, acetophenone analog **22** had less UT inhibition activity than **3** and sulfonamide **24** was inactive compared to corresponding fluorenone analog **9**, which showed strong inhibition. This result suggests that the 3D structure of the fluorenone core is important to UT inhibition. Fluorenones with 2,7-disubstituents have a crescent-like shape, which is lost when substituted with biphenylacetone. Increasing flexibility of the acetophenone moiety reduced UT inhibition activity.

Computational docking simulations were done to propose binding modes for the most potent UT-A1 inhibitor **3**, and the most potent UT-B inhibitor **8**. Structures for rat UT-A1 and UT-B were generated by homology modeling as described,¹⁰ based on the high resolution X-ray crystal structure of bovine UT-B solved at 2.5Å.²⁹ Our homology models of these two proteins contain sites that appear homologous to narrow constriction (Sm) and low energy urea binding sites (So and Si) observed in the bovine UT-B template structure.

Fig. 5A shows docked conformations of inhibitor **3** bound to UT-A1 and UT-B. The lowest energy conformation of this molecule docked into both proteins in similar orientations. The planar inhibitor scaffold docked into the outer part of the UT-A1 and UT-B pore region, not binding deeply into the channel. In the docked conformation of **3** with UT-A1 the amido NH₂ group projects into a pocket surrounded by Glu⁵⁷², Val⁶⁰³, Asn⁶⁰⁴, Phe⁸³² and Tyr⁹⁰⁰. The bis-urea inhibitor **8**, which shows a greater potency for UT-B, is shown for comparison (Fig. 5B), and docks in a similar manner as **3**. Other active analogs of **3** also docked similarly. The position of the inhibitor scaffolds do not overlap the putative cytoplasmic urea binding site (Si) near Gln⁵⁹⁹, which is homologous to Gln⁶³ in the selenourea-bound template structure.²⁸ Taken together with urea competition experiments for **3**, the proposed binding site in Fig. 5 is consistent with a non-competitive inhibition mechanism.

Conclusions

In conclusion, we identified by high-throughput screening symmetrical 2,7-disubstituted fluorenones as novel UT inhibitors, and established structure-activity relationships by synthesis and characterization of 22 analogs. Functional studies indicated reversible inhibition of UT-A1 urea transport by the 2,7-disubstituted fluorenone analogs by a non-competitive inhibition mechanism. Docking computations suggested inhibitor binding at the UT outer pore regions at a site distinct from the putative urea binding site. Finally, analysis of inhibitor metabolism indicated carbonyl reduction by reductase and subsequent base-catalyzed elimination.

Experimentals

Synthesis

All chemical synthetic procedures and characterizations are described in supplementary information.

Cell culture

Triply transfected MDCK cells expressing rat UT-A1, yellow fluorescent protein (YFP)-H148Q/V163S and human aquaporin-1 (AQP1) were grown in Dulbecco's modified Eagle medium, 10% FBS and three selection antibiotics (zeocin, geneticin and hygromycin B), as described.¹⁴

UT-A1 inhibition assay

MDCK-UT-A1-AQP1-YFP cells were used for UT-A1 inhibition assay as described.¹⁴ Briefly, after incubation for 15 min with compounds the cells were subjected to a 800 mM urea gradient and cellular YFP fluorescence was continuously measured with a plate reader (model Infinite M1000, Tecan Trading AG, Switzerland). UT-A1 inhibition alters the profile of the curve, increasing the initial shrinkage (decreased fluorescence) and slowing reswelling (increased fluorescence). Percentage UT-A1 inhibition was computed as $100\% (F_{\text{neg}} - F_{\text{test}}) / (F_{\text{neg}} - F_{\text{pos}})$, where F is fluorescence measured 7 s after urea injection for the negative control (F_{neg}), test compound (F_{test}) and positive control (F_{pos}).

UT-B inhibition assay

As described,¹⁵ whole rat blood was diluted to a hematocrit of ~1.5% in PBS containing 1.25 M acetamide. Erythrocyte suspensions were incubated for 15 min with test compounds and then rapidly mixed with PBS. Percentage lysis was quantified from absorbance at 710 nm as: $100\% (A_{\text{neg}} - A_{\text{test}}) / (A_{\text{neg}} - A_{\text{pos}})$, where A is absorbance for the negative control (A_{neg}), test compound (A_{test}) and positive control (A_{pos}) at 710 nm.

Functional studies

Reversibility was tested by incubation of inhibitors at a concentration near their IC_{50} and then washing with PBS before UT-A1 inhibition assay. Competition with urea was studied using different concentrations of urea (80 to 1,600 mM) in the UT-A1 inhibition assay.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Supported by grants DK101373, DK35124, DK72517, EB00415 and EY13574 from the National Institutes of Health. The authors acknowledge OpenEye Scientific (Santa Fe, NM, USA) for its Academic Site License program.

Notes and references

1. Klein JD, Blount MA, Sands JM. Urea transport in the kidney. *Compr Physiol*. 2011; 2:699–729. [PubMed: 23737200]
2. Smith CP. Mammalian urea transporters. *Exp Physiol*. 2009; 94:180–185. [PubMed: 19028811]
3. Fenton RA, Chou CL, Stewart GS, Smith CP, Knepper MA. Urinary concentrating defect in mice with selective deletion of phloretin-sensitive urea transporters in the renal collecting duct. *Proc Natl Acad Sci*. 2004; 101:7469–7474. [PubMed: 15123796]
4. Fenton RA, Flynn A, Shodeinde A, Smith CP, Schnermann J, Knepper MA. Renal phenotype of UT-A urea transporter knockout mice. *J Am Soc Nephrol*. 2005; 16:1583–1592. [PubMed: 15829709]
5. Uchida S, Sohara E, Rai T, Ikawa M, Okabe M, Sasaki S. Impaired urea accumulation in the inner medulla of mice lacking the urea transporter UT-A2. *Mol Cell Biol*. 2005; 25:7357–7363. [PubMed: 16055743]
6. Klein JD, Frohlich O, Mistry AC, Kent KJ, Martin CF, Sands JM. Transgenic mice expressing UT-A1, but lacking UT-A3, have intact urine concentration ability. *FASEB J*. 2013; 27:1111–1117.
7. Yang B, Bankir L, Gillespie A, Epstein CJ, Verkman AS. Urea-selective concentrating defect in transgenic mice lacking urea transporter UT-B. *J Biol Chem*. 2002; 277:10633–10637. [PubMed: 11792714]
8. Yao C, Anderson MO, Zhang J, Yang B, Phuan PW, Verkman AS. Triazolothieno-pyrimidine inhibitors of urea transporter UT-B reduce urine concentration. *J Am Soc Nephrol*. 2012; 23:1210–1220. [PubMed: 22491419]
9. Li F, Lei T, Zhu J, Wang W, Sun Y, Chen J, Dong Z, Zhou H, Yang B. A novel small-molecule thienoquinolin urea transporter inhibitor acts as a potential diuretic. *Kidney Int*. 2013; 83:1076–1086. [PubMed: 23486518]
10. Esteva-Font C, Cil O, Phuan PW, Su T, Lee S, Anderson MO, Verkman AS. Diuresis and reduced urinary osmolality in rats produced by small-molecule UT-A-selective urea transport inhibitors. *FASEB J*. 2014; 28:3878–3890. [PubMed: 24843071]
11. Knepper MA, Miranda CA. Urea channel inhibitors: a new functional class of aquaretics. *Kidney Int*. 2013; 83:991–993. [PubMed: 23728001]
12. Sands JM. Renal urea transporters. *Curr Opin Nephrol Hypertens*. 2004; 13:525–532. [PubMed: 15300159]
13. Esteva-Font C, Anderson MO, Verkman AS. Urea transport proteins as drug targets. *Nat Rev Nephrol*. 2015; 11:113–123. [PubMed: 25488859]
14. Esteva-Font C, Phuan PW, Anderson MO, Verkman AS. A small molecule screen identifies selective inhibitors of urea transporter UT-A. *Chem Biol*. 2013; 20:1235–1244. [PubMed: 24055006]
15. Levin MH, De la Fuente R, Verkman AS. Urearetics: a small molecule screen yields nanomolar potency inhibitors of urea transporter UT-B. *FASEB J*. 2007; 21:551–563. [PubMed: 17202246]
16. Mayer GD, Krueger RF. Tilorone hydrochloride: mode of action. *Science*. 1970; 169:1214–1215. [PubMed: 4317924]
17. Krueger RF, Mayer GD. Tilorone hydrochloride: an orally active antiviral agent. *Science*. 1970; 169:1213–1214. [PubMed: 4317923]

18. Svensson CK, Knowlton PW. Effect of the immunomodulator tilorone on the in vivo acetylation of procainamide in the rat. *Pharm Res.* 1989; 6:477–480. [PubMed: 2474808]
19. Perry PJ, Read MA, Davies RT, Gowan SM, Reszka AP, Wood AA, Kelland LR, Neidle S. 2,7-Disubstituted Amidofluorenone Derivatives as Inhibitors of Human Telomerase. *J Med Chem.* 1999; 42:2679–2684. [PubMed: 10411488]
20. Lee CC, Chang DM, Huang KF, Chen CL, Chen TC, Lo Y, Guh JH, Huang HS. Design, synthesis and antiproliferative evaluation of fluorenone analogs with DNA topoisomerase I inhibitory properties. *Bioorg Med Chem.* 2013; 21:7125–7133. [PubMed: 24094433]
21. Zhou D, Tuo W, Hu H, Xu J, Chen H, Rao Z, Xiao Y, Hua X, Liu P. Synthesis and activity evaluation of tilorone analogs as potential anticancer agents. *Eur J Med Chem.* 2013; 64:432–441. [PubMed: 23665799]
22. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev.* 2001; 46:3–26. [PubMed: 11259830]
23. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug Candidates. *J Med Chem.* 2002; 45:2615–2623. [PubMed: 12036371]
24. Fletcher TL, Taylor ME, Dahl AW. Derivatives of fluorine. I. N-Substituted 2-aminofluorene and 2-aminofluorenone. *J Org Chem.* 1955; 20:1021–1025.
25. Perry CJ, Holding K, Tyrrell E. Simple, novel synthesis for 1-carbamoyl-1H-benzotriazole and some of its analogs. *Syn Commun.* 2008; 38:3354–3365.
26. Snyder DS, Tradtrantip L, Yao C, Kurth MJ, Verkman AS. Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. *J Med Chem.* 2011; 54:5468–5477. [PubMed: 21707078]
27. Ritter CL, Decker RW, Malejka-Giganti D. Reduction of nitro and 9-oxo groups of environmental nitrofluorenes by the rat mammary gland in vitro. *Chem Res Toxicol.* 2000; 13:793–800. [PubMed: 10956068]
28. Compound 25: ¹H NMR (DMSO-*d*₆) δ 10.13 (brs, 1H), 7.78 (brs, 1H), 7.57 (d, 1H, *J* = 8.0 Hz), 7.37 (d, 1H, *J* = 7.8 Hz), 7.28 (d, 1H, *J* = 8.0 Hz), 6.79 (brs, 1H), 6.66 (d, 1H, *J* = 8.1 Hz), 5.57 (brs, 1H), 2.55 (s, 3H), 2.05 (s, 3H); LRMS (ESI) *m/z* 279 (M+H)⁺.
29. Levin EJ, Cao Y, Enkavi G, Quick M, Pan Y, Tajkhorshid E, Zhou M. Structure and permeation mechanism of a mammalian urea transporter. *Proc Natl Acad Sci.* 2012; 109:11194–11199. [PubMed: 22733730]

Fig 1.

Discovery of 2,7-disubstituted fluorenone **3** as UT-A1 inhibitor. A. Structure of **3** and concentration-inhibition data for inhibition of rat UT-A1 and UT-B urea transporters. Fitted parameters: IC_{50} 1μM and 1.5μM, Hill coefficient 0.9 and 1.1, for UT-A1 and UT-B respectively. B. Strategy for analogs synthesis for SAR analysis.

Fig. 2. Urea transport inhibition by 2,7-disubstituted fluorenones. A. Concentration-inhibition data for UT-A1 and UT-B for 3, 11, 14 and 19. B. Primary data from UT-A inhibition assay showing reversibility, inhibition kinetics and urea competition for **3**. Phloretin concentration was 0.35 mM.

Fig. 3. In vitro metabolic stability of disubstituted fluorenones. Compounds incubated with hepatic microsomes in the presence of NADPH. A. LC/MS showing disappearance of **3** and appearance of metabolite over 60 min. B. Kinetics of disappearance of **3**, **17**, **20**, and **22** over 60 min.

Fig. 4.
Proposed mechanism of hepatic metabolism of **3**.

Fig. 5. Computational docking of **3** and **8** to homology models of rat UT-A and UT-B. Zoomed -in and zoomed-out representations of (A) inhibitor **3** bound to rat UT-A and UT-B cytoplasmic domains; and (B) the most potent UT-B inhibitor **8** bound to the rat UT-B cytoplasmic domain.

Scheme 1.

Synthesis of 2,7-bisalkylamidofluorenone and 2,7-bissulfonamidofluorenone analogs.

Reaction conditions and reagents: (a) Na₂S-9H₂O, NaOH, EtOH, 78%; (b) Et₃N, THF, Ac₂O for **3**, propionyl chloride for **4**; isobutyryl chloride for **5**; butyryl chloride for **6**; (c) CF₃CO₂H in a sealed tube for **7**; (d) KNCO, AcOH/H₂O for **8**; (e) MsCl, pyridine, THF for **9**; (f) 3-chloropropanesulfonyl chloride, pyridine, CH₂Cl₂; then, K₂CO₃, CH₃CN, reflux, for **10**.

Scheme 2.

Synthesis of extended 2,7-bisacetylamidofluorenone analogs. Reaction conditions and reagents: (a) bromoacetyl bromide, xylene, reflux, 40%; (b) benzyloxyacetyl chloride, xylene, reflux, 26% for **15**; (c) maleic anhydride, CHCl₃, 26% for **16**; (d) NaOH, EtOH, 86% for **12**; (e) methoxyethanol, NaH, CH₃CN, 18% for **13**; (f) NaN₃, DMF, 24% for **14**.

Scheme 3.

Synthesis of carbonyl-modified fluorenone analogs. Reaction conditions and reagents: (a) NH₂OH-HCl, DMSO/H₂O, 22%; (b) NaBH₄, CH₃CN/MeOH (10/1), 28%; (c) Et₃N, THF, Ac₂O, 65%; (d) Et₃N, THF, Ac₂O, 62% for **22**; Benzyloxyacetyl chloride, xylene, reflux, 46% for **23**; (e) MsCl, pyridine, THF, 23%.

Table 1

Inhibition of UT-A1 and UT-B urea transport by 2,7-disubstituted fluorenoneanalogs.

Structure	Functional group	UT- A1 IC ₅₀ (μM)	UT-B IC ₅₀ (μM)
1	>50	>50
R		
	2 H	>50	>50
	3 COCH ₃	1	1.5
	4 COCH ₂ CH ₃	15	5
	5 COCH(CH ₃) ₂	18	50
	6 CO(CH ₂) ₂ CH ₃	>50	>50
	7 COCF ₃	10	7.5
	8 CONH ₂	2	1.2
	9 SO ₂ CH ₃	1.5	2.5
	10 SO ₂ (CH ₂) ₃	>50	>50
	11 COCH ₂ Br	30	10
	12 COCH ₂ OH	20	25
	13 COCH ₂ O(CH ₂) ₂ OMe	>50	50
	14 COCH ₂ N ₃	20	30
	15 COCH ₂ OBn	>50	>50
	16 CO(CH ₂) ₂ CO ₂ H	30	>50
X		
	17 CNHOH	12	25
	18 CHOH	>50	20
	20 SO ₂	15	2
R		
	21 H	>50	>50
	22 COCH ₃	18	20
	23 COCH ₂ OBn	>50	>50
	24 SO ₂ CH ₃	>50	30